Mechanism
Thermogenesis and energy expenditure
Most of the weight-loss effect of GLP-1 medicines comes from reduced food intake. With glucagon-receptor agonism (in dual or triple agonists), there is also evidence for an increase in energy expenditure, which adds to the calorie-deficit driver of weight loss.
Plain-English explanation
Most of the weight-loss effect of GLP-1 medicines comes from reduced food intake. With glucagon-receptor agonism (in dual or triple agonists), there is also evidence for an increase in energy expenditure, which adds to the calorie-deficit driver of weight loss.
Research-level explanation
Indirect calorimetry and isotope studies in early-phase research suggest a measurable but modest energy-expenditure component for glucagon-receptor-containing combinations. Outcome implications remain to be defined.
Common misconceptions
| Common claim | More accurate framing |
|---|---|
| GLP-1 medicines speed up metabolism. | Pure GLP-1 mono-agonism is principally an appetite-suppression mechanism; energy-expenditure increase is more closely associated with glucagon-receptor agonism in combinations. |
Safety relevance
Heart rate increases observed with some agents; cardiovascular monitoring during therapy is appropriate per the relevant product information.
- Modest energy-expenditure increases in preclinical or early-phase studies do not establish that thermogenic effects dominate the clinical outcome.
Related peptide profiles
Related trials
Related conditions
Related safety signals
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Peer-reviewed publicationJastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med 2023.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for medicines and medical devices
- Regulatory document (MHRA/EMA/FDA)European Medicines Agency — Scientific guidelines
EMA scientific guidelines covering pharmacodynamic mechanisms
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial summary of mechanism profiles on this site